Therefore, HO‐1 inducer‐loaded PBP‐NPs were considered to be novel therapeutics for obesity‐induced metabolic syndromes such as T2DM and NASH occurred by adipose tissue dysfunction with excessive NEFA, inflammation, and oxidative stress. This evidence concerns the gene HMOX1 and metabolic dysfunction-associated steatohepatitis.